Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

14 décembre 2017

08:30
Scientists have taken a significant step forward in efforts to harness our own white blood cells to fight deadly cancers. A pilot study, funded by Montefiore Einstein Center for Cancer Care, in partnership with New York Blood Center (NYBC), has...

08:30
Renovatm Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...

08:00
Trovagene, Inc. , a precision medicine biotechnology company, engaged in the development of targeted cancer therapies, today announced the filing of its protocol for a Phase 2 clinical trial of PCM-075 in combination with abiraterone acetate (Zytiga®...

08:00
OncoSec Medical Incorporated ("OncoSec" or the "Company") , a company developing intratumoral cancer immunotherapies, today announced the initiation of patient dosing in PISCES/KEYNOTE-695, the company's global, multi-center, registration-directed...

07:15
Ampio Pharmaceuticals, Inc. today reported that the Phase 3 clinical trial of Ampiontm met its primary endpoint with 71% of Ampiontm treated patients meeting the OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30%...

06:30
Protagonist Therapeutics, Inc. today announced final top-line results from the randomized, placebo-controlled, single ascending- and repeat-dose Phase 1 study of PTG-300, the company's injectable hepcidin mimetic peptide, in normal healthy...

04:00
Namilumab exclusive worldwide licence granted by Takeda  Awarded £1.35 million grant by Innovate UK to support phase II proof-of-concept study  Highly experienced management team; co-founded by serial entrepreneur Bryan Morton   Izana...

01:30
reMYND and Novo Nordisk have entered into a license agreement to further develop reMYND's ReS39 therapeutic program of diabetes. This program holds also promise for NASH and the metabolic syndrome.        (Logo:...


13 décembre 2017

14:36
Prolong Pharmaceuticals announced today that it has completed enrollment in its Phase II study to evaluate SANGUINATE® in the treatment of vaso-occlusive crisis in patients with sickle cell disease (SCD). SANGUINATE® is a first-in-class...

12:44
The National Institutes of Health (NIH) announced a $70 million grant to create and implement a national consortium of clinical researchers to advance Alzheimer's research.  The newly formed ACTC includes many GAP-Net research sites supported by the...

11:57
A new research initiative by the University of Maryland's Institute for Bioscience and Biotechnology Research (IBBR) and the University of Pittsburgh could finally uncover how T-cells?the "killer cells" that defend the body from microbes?are alerted...

11:46
Hovione announced today enrollment of the first patient in MARS (Minocycline Against Rosacea Study), a Phase 2 clinical study of topical minocycline (HY01) in moderate to severe papulopustular rosacea patients. MARS is a multi-center, randomized,...

11:17
Tandis que l'Australie a été confrontée à l'une des saisons grippales les plus dures depuis des décennies[1], Eurocine Vaccines se prépare pour la phase de développement suivante, une deuxième étude clinique sur son premier vaccin candidat Immunosetm...

11:04
While Australia has faced one of the harshest influenza seasons of decades[1], Eurocine Vaccines prepares for the next phase of development, a second clinical study with its first vaccine candidate Immunosetm FLU, to fight the same.       (Photo:...

10:00
TriNetX, the global health research network for healthcare organizations, biopharmaceutical companies, and Contract Research Organizations (CROs), today announced the general availability of its Natural Language Processing (NLP) service. TriNetX's...

09:33
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and personalized medicine for early stage breast cancer, announced today the results from last week's oral presentation at the San Antonio Breast Cancer Symposium. The results...

09:30
Ability Pharmaceuticals SL, a biopharmaceutical company, announced today that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application which allows AbilityPharma to proceed with a phase 1/2a...

08:00
Audentes Therapeutics, Inc. , a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of Mark A. Goldberg, M.D. to its...

08:00
Sirenas, LLC ("Sirenas"), a biotechnology company harnessing computational approaches to discover therapeutics derived from nature's chemistry, announced that it has received a new grant from the Bill & Melinda Gates Foundation to advance ATLANTIStm,...

07:30
MabVax Therapeutics Holdings, Inc. , a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today the completion of enrollment and dosing of...

06:30
BioLife Solutions, Inc. , the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media ("BioLife" or the "Company"), today announced that it has executed an agreement to supply its CryoStor® cell freeze media...

01:01
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive topline results from a pivotal Phase 2 clinical study of cemiplimab in 82 patients with advanced cutaneous squamous cell carcinoma (CSCC), the second deadliest skin cancer after...


12 décembre 2017

18:43
AXON a annoncé le lancement d'un recrutement ouvert dans le cadre de l'étude de phase 1 actuellement en cours chez des patients souffrant de la variante non-fluente de l'aphasie primaire progressive (APP-vnf). Les données obtenues à partir de la...

10:55
AXON has announced the initiation of open recruitment in the currently running Phase 1 study in patients suffering from the non-fluent variant of Primary Progressive Aphasia (nfvPPA). The data obtained from the initial 18-week period which assess a...

10:41
Results from the pooled analysis presented at the American Epilepsy Society Annual Meeting 2017 in Washington DC, US.[1],[2],[3]   Bial and Eisai have announced new real-world audit data presented at the American Epilepsy Society (AES) Annual...

10:28
Plitidepsin showed the capability to cancel out the activity of the osteoclasts -cells responsible for the destruction of bone- at a concentration of up to 100 times less than we believe necessary to kill myeloma cells In combination with proteasome...

10:27
The U.S. Food and Drug Administration today expanded the approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, an inflammation in the...

08:00
Boehringer Ingelheim has initiated GioTag, a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). Data from approximately 190 patients who received tyrosine...

08:00
Two studies presented yesterday at the American Society of Hematology's annual meeting in Atlanta showed frequent expression of CD74, a cell-surface protein in hematologic B-cell malignancies, in both heavily-pretreated and never-treated multiple...

07:51
For EU media only ? not for US journalists Hokusai-VTE CANCER study is a phase 3b, prospective, randomised, open-label, blind end-point (PROBE) study evaluating edoxaban versus low molecular weight heparin (LMWH) dalteparin in venous...

07:45
Janssen Research & Development, LLC today announced data from the Phase 3 ALCYONE study, showing that DARZALEX® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing...

07:34
In four clinical trials being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report promising results suggesting patients with blood disorders and several types of cancer...

07:31
Daiichi Sankyo, Inc., (hereafter, Daiichi Sankyo), today announced results from the Hokusai-VTE CANCER study evaluating oral edoxaban (known by the brand names SAVAYSA® in the U.S. and LIXIANA® outside the U.S.), and found that edoxaban is...

07:30
AbbVie , a research and development based global biopharmaceutical company, today announced the first presentation of efficacy and safety results from MURANO, an international, multicenter, open-label, randomized Phase 3 study of...

07:00
Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announces the first patient has been dosed in its Phase 2 study of PR013, the Company's topical...

07:00
BTG plc (LSE: BTG), a global specialist healthcare company, today announced that following positive results of its 15-year experience between 2003 and 2017 with TheraSphere®, Northwestern University, Illinois has adopted Y90 transarterial...

06:30
TapImmune Inc. , a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that the first patient has been enrolled in a Phase 2 randomized, multi-center, double-blinded,...

06:00
AliveCor, the leader in FDA-cleared personal electrocardiogram (EKG) technology, today announced issuance of a U.S. patent which covers the use of data collected from wearable devices as a means of assisting diagnoses of heart arrhythmias, including...


11 décembre 2017

18:00
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that preliminary safety and efficacy data from a phase 1 study of DS-3201, an investigational and potential first-in-class EZH1/2 dual inhibitor, in patients with relapsed or...

17:15
Janssen Research & Development, LLC today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery of DARZALEX® (daratumumab) had a manageable safety profile and a 12 percent rate of infusion...

16:30
In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the U.S. Food and Drug Administration (FDA) found significant gaps in participation among those aged 75 and older when considered...

16:26
For patients with advanced leukemia, access to high-quality end-of-life care appears to be reduced in those dependent on blood transfusions, according to a new study being presented during the 59th American Society of Hematology (ASH) Annual Meeting...

16:05
TapImmune Inc. , a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that Peter Hoang, President and Chief Executive Officer, is now available for on-demand viewing at...

16:00
Amgen today announced new results showing the positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint of OS, demonstrating that the addition of KYPROLIS® (carfilzomib) to...

14:45
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today the first reported data of the investigational agent gilteritinib from the ongoing, open-label, dose escalation/expansion Phase 1 study (NCT02236013)...

14:31
Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") announced today that the results of the Global Phase 3 study (MAVORIC: Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) investigating the use of...

12:36
Aesculap Biologics, LLC is pleased to announce the launch of its redesigned website. The new website has a clean, uncluttered design, improved functionality, and enhanced rich content to provide both healthcare professionals and patients with...

11:03
Results from a post hoc subgroup analysis of the Phase II SUSTAIN study show that crizanlizumab, an investigational humanized anti-P-selectin monoclonal antibody, delayed the time to first sickle cell pain crisis (SCPC) in patients vs. placebo in key...

10:00
BioMarin Pharmaceutical Inc. announced updates on valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy treatment for severe hemophilia at ASH. Efficacy Data with Valoctocogene Roxaparvovec...

10:00
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a Sponsored Research Agreement (SRA) with The Rockefeller University to expand its research efforts around the mechanisms by which the CA125 tumor shed antigen...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16